IDACORP, Inc. reported first quarter 2024 net income attributable to IDACORP of $48.2 million, or $0.95 per diluted share, compared with $56.1 million, or $1.11 per diluted share, in the first.
IDACORP, Inc. reported fourth quarter 2023 net income attributable to IDACORP of $31.3 million, or $0.61 per diluted share, compared with $42.1 million, or $0.83 per diluted share, in the fourth.
Redx Pharma PLC on Wednesday said its half-year loss nearly doubled, due to lower revenue and higher expenses, but it noted progress in therapeutics trials and said it retains the foundations for. | May 17, 2023